BridgeBio to Report Phase 3 Encaleret Results on Oct. 29
BridgeBio is set to release topline results from CALIBRATE, its Phase 3 study in autosomal dominant hypocalcemia type 1...
Creative Medical Tech Gains $4.2M in Warrant Exercise Deal
Creative Medical Technology secured approximately $4.2 million in gross proceeds through the immediate exercise of 1,116,136 previously issued, registered...
Wave’s Surging Obesity Drug Shows Promising Trial Results
Single-dose WVE-007 reduced circulating Activin E by 56% at 75 mg, 75% at 240 mg, and 85% at 400...
Wave Life Sciences Sees Positive Data for Obesity Drug WVE-007
Wave reported dose-dependent, single-dose reductions in circulating Activin E at day 29 in its INLIGHT obesity study: 85% at...
Tectonic’s TX45 Shows Positive Data in Phase 1b PH Trial
TX45 produced acute, directionally favorable hemodynamic and echocardiographic changes in PH-HFrEF after a single intravenous dose: pulmonary capillary wedge...
Immuron’s Latest Clinical Trial Update: A New Perspective
No new efficacy results were released. The Uniformed Services University Phase 2 traveler’s diarrhea field study of Travelan (n=851;...
Olema Presents Palazestrant OPERA-02 Trial at SABCS 2025
Olema will bring a trial‑in‑progress poster for its Phase 3 OPERA‑02 study to SABCS, detailing a randomized, double‑blind comparison...
BioCardia’s Pivotal Heart Failure Trial Enrolls First Patient
In BioCardia’s earlier CardiAMP-HF study, the composite endpoint of all-cause death, nonfatal major adverse cardiac events, and a validated...
PDS Biotech to Present New Cancer Therapy Data at SITC 2025
PDS Biotechnology’s National Cancer Institute collaborators will deliver three presentations at SITC 2025, headlined by a rapid oral on...
Breakthrough Oral Semaglutide Pill Shows Preclinical Promise
Preclinical data to be presented at ObesityWeek 2025 indicate that Rani Therapeutics’ oral semaglutide candidate (RT-116), delivered via the...